Currency In USD
| Previous Close | 90.43 |
| Open | 92.84 |
| Day High | 105 |
| Day Low | 91.74 |
| 52-Week High | 105 |
| 52-Week Low | 36.65 |
| Volume | 2.87M |
| Average Volume | 617,461 |
| Market Cap | 8.18B |
| PE | -27.78 |
| EPS | -3.58 |
| Moving Average 50 Days | 83.31 |
| Moving Average 200 Days | 73.83 |
| Change | 9.02 |
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
GlobeNewswire Inc.
Mar 10, 2026 11:00 AM GMT
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced th
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewswire Inc.
Jan 29, 2026 12:00 PM GMT
Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) --